MicroMediom Selected for 2025 Agri-Food Venture Support Program Supported by the Seoul Center of the Korea Agricultural Technology...

MicroMediome Selected as Resident Startup at Seoul Bio Hub MicroMediome has been selected as one of 12 promising startups to join Seoul...

MicroMediome, a bio-healthcare company specializing in microbiome-based cancer therapy and healthcare solutions, has been selected for...

KDB NextRound is a startup IR (Investor Relations) event organized by Korea Development Bank (KDB). This event featured IR presentations...

MicroMediom, a start-up founded by professors from Korea University College of Medicine, has been honored with the K-R&D Award at the...

We are thrilled to announce that our project has been awarded the prestigious honor for exceptional performance and contribution in 2023....

Seoul – MicroMediome, a company based in Korea University Campus Town, announced on the 22nd that it has donated goods worth 10.4 million...

MicroMediome is a startup that conducts research in the fields of oncology treatment, vaccines, drug delivery systems, and more,...

In June 2023, Micromediome successfully secured a seed investment of 300 million KRW from Synergy IB Corporation.

의정부시, 바이오클러스터 조성 워킹그룹 신설참여 2023.2.26 https://www.etnews.com/20230226000126

마이크로바이옴 상용화 현황 및 전망 : 과학기술정보통신부 바이오아이코어사업단 강의 2023.02. https://www.youtube.com/watch?v=FDJjS3WOwdo

Contents

Contents

Contents